Pharmaceutical - Johnson & Johnson, Neurological

Filter

Popular Filters

1 to 25 of 30 results

Global epileptic anticonvulsants market - 2014-2020

Global epileptic anticonvulsants market - 2014-2020

16-07-2014

North America dominates the global epileptic anticonvulsants market and is followed by Europe, according…

Abbott LaboratoriesAsia PacificBusiness FinanceEpilepsyGlaxoSmithKlineGlobalHealth Medical PharmaHealth Medical PharmaJohnson & JohnsonMarkets & MarketingNeurologicalNovartisPfizerPharmaceuticalUCB

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

07-05-2014

US health care giant Johnson & Johnson subsidiary Janssen Pharmaceuticals has released positive results…

Invega SustennaJanssenJohnson & JohnsonNeurologicalPharmaceuticalRegulationResearch

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

11-04-2014

The US Food and Drug Administration’s recent approval of Johnson & Johnson subsidiary Janssen’s Topamax…

JanssenJohnson & JohnsonMarkets & MarketingNeurologicalPharmaceuticalRegulationTopamax

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

20-03-2014

Following an Independent Data Monitoring Committee recommendation based on positive efficacy, a Johnson…

Invega SustennaJanssenJohnson & JohnsonNeurologicalpaliperidone palmitatePharmaceuticalResearch

New data show Janssen’s Xeplion significantly delays time to relapse vs oral antipsychotic monotherapy

New data show Janssen’s Xeplion significantly delays time to relapse vs oral antipsychotic monotherapy

05-03-2014

Janssen Pharmaceutica, a European subsidiary of US health care giant Johnson & Johnson released positive…

Janssen PharmaceuticaJohnson & JohnsonNeurologicalPharmaceuticalResearchXeplion

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

14-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to fund paliperidone…

Eli LillyHealthcareInvega SustennaJohnson & JohnsonNeurologicalNew ZealandPharmaceuticalPricingRisperdal ConstaZyprexa Relprevv

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Janssen reveals new data on Xeplion in various stages of schizophrenia

Janssen reveals new data on Xeplion in various stages of schizophrenia

30-11-2013

US health care giant Johnson & Johnson’s (NYSE: JNJ) Europe-based subsidiary Janssen Pharmaceutica…

Invega SustennaJanssen PharmaceuticaJohnson & JohnsonNeurologicalPharmaceuticalResearchXeplion

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis

01-02-2013

The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

Regulatory briefs from Astellas, Janssen, Biogen and Elan, and QRxPharma

17-01-2013

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says the US Food and Drug Administration…

Anti-viralsAstellas PharmaBiogen IdecBiotechnologyElanEuropeJanssenJohnson & JohnsonMoxDuoNeurologicalNorth AmericaOncologyPharmaceuticalPrezistaQRxPharmaRegulationTarcevaTysabri

Evotec in up to $175 million NMDA antagonist license deal with Janssen

19-12-2012

Germany's Evotec (EVT: TecDAX) has entered into a license agreement with Janssen Pharmaceuticals, a subsidiary…

EvotecJanssenJohnson & JohnsonLicensingNeurologicalPharmaceutical

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches

16-12-2012

The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing…

BiotechnologyfulranumabGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalTakeda Pharmaceuticalstanezumabtapentadol

FDA OKs new indication for Janssen's Nucynta and fast tracks Zytiga sNDA

30-08-2012

There were two pieces of good news for US health care giant Johnson & Johnson (NYSE: JNJ) subsidiaries…

BiotechnologyJanssenJohnson & JohnsonNeurologicalNorth AmericaNucyntaOncologyPharmaceuticalRegulationZytiga

US surveyed PCPs and pain specialists experienced reimbursement restrictions for Janssen's Nucynta ER

28-08-2012

The majority of US surveyed primary care physicians (PCPs) and pain specialists indicate that they have…

JanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaNucyntaPfizerPharmaceuticalPricingtanezumab

J&J and Pfizer drop bapineuzumab development for Alzheimer's

07-08-2012

There was disappointing - though not really unexpected - news yesterday for US health care giant Johnson…

bapineuzumabElanJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's

24-07-2012

US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that the co-primary clinical endpoints, change…

bapineuzumabJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox

26-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published…

AllerganBotoxEuropeGlaxoSmithKlineHerceptinJanssenJohnson & JohnsonNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarcevaTyverbZytiga

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna

12-06-2012

USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started…

AlkermesInvega SustennaJohnson & JohnsonNeurologicalPharmaceuticalResearch

FDA delays once-a-day Prezista approval; finds counterfeit of Teva's Adderall

30-05-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Therapeutics division has received a complete…

AdderallAnti-viralsGenericsJanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPrezistaRegulationTeva Pharmaceutical Industries

Positive Ph III results for J&J's Nucynta in diabetic peripheral neuropathy

18-05-2012

Janssen Pharmaceuticals, a unit of health care major Johnson & Johnson yesterday announced the results…

DiabetesJanssenJohnson & JohnsonNeurologicalNucyntaPharmaceuticalResearch

Tapentadol ER has advantages over Lyrica in reducing diabetic neuropathy pain intensity

21-03-2012

Surveyed US neurologists and managed care organization (MCO) pharmacy directors agree that reducing pain…

DepomedGraliseJohnson & JohnsonLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticaltapentadol

1 to 25 of 30 results

Back to top